Onkos Surgical

Bacterial contamination of implants is a problem. Even with advancements in contemporary operating room precautions, the problem persists.

Onkos has been granted FDA De Novo authorization for a groundbreaking technology that protects the implant from bacteria that deposit on its surface prior to implantation. This technology has been shown in pre-clinical studies to reduce bacterial load on the surface of an implant.

Additionally, preclinical testing demonstrated that the technology has not been shown to contribute to bacterial resistance.

Contact us here to learn more: https://onkossurgical.com/contact-us/

Today marks a significant milestone, not just for Onkos Surgical, but for the orthopaedic industry as a whole!

We are proud and thrilled to announce that the U.S. Food & Drug Administration (FDA) has granted De Novo approval for a novel, antibacterial coated implant technology…the first of its kind in the U.S. orthopaedic market.

“Implant contamination is a growing concern to the orthopaedic surgical community,” said Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College Endowed Professor of Orthopaedic Oncology, and Director, Musculoskeletal Oncology at Rush Cancer Center. “When bacteria contaminate the artificial joint, it can lead to a cascade of issues that can significantly impact the patient’s health. The current tools in our armamentarium are simply not enough to help solve this multifactorial problem.”

“When it comes to implant bacterial contamination and failure, patient complications may include decreased limb function, amputation, and increased rates of mortality…This exciting technology has the potential to be one of the most important advances in orthopedic medical devices in decades,” said Patrick Treacy, Onkos Surgical Founder and CEO.”

We look forward to sharing more in the coming days and weeks. Learn more about this pivotal announcement here: https://bit.ly/43SlYKL

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and...

When you are deciding the best treatment option for your pediatric sarcoma patients, having an implant solution that fits both their growth and their broader treatment window is critical.

At Onkos, we understand the importance of reliable delivery to meet surgery dates within treatment windows, especially for sarcoma patients. With the JTS, we have dedicated tremendous resources and focused our efforts on reducing lead times and increasing consistency in delivery.

As of November, we have consistently reduced JTS lead times by more than 50%, from 16 weeks to 8 weeks or less. Every member of our team embodies dedication, pride, and expertise for the JTS and for this work, and we are grateful for them!

Learn more about the Juvenile Tumor System here: https://onkossurgical.com/jts-extendible-prosthesis/

Contact us with any questions about using the JTS here: [email protected]

JTS Extendible Prosthesis - Onkos Surgical The Juvenile Tumor System (JTS) is a patient-specific, extendible prosthesis that achieves lower limb length equality over time, in an outpatient setting following bone cancer surgery.